Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

ANIP

ANI PHARMACEUTICALS INC

Pharmaceutical Preparations · SIC 2834CIK 1023024Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$883.0M
Net Income FY2025
$78.0M
EPS (Basic, as reported)
$3.50
Net Margin FY2025
8.9%
ROE FY2025
14.5%
Total Equity
$541.0M
Shares Out
24M
Business description

ANI PHARMACEUTICALS INC — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 129 → 883 +23.8% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue129177202207208216316487614883
Cost of revenue(49)(79)(73)(63)(87)(101)(139)(182)(250)(341)
Research & development(3)(9)(15)(20)(16)(11)(22)(34)(45)(52)
Selling, general & administrative(28)(32)(44)(56)(65)(84)(124)(162)(250)(318)
General & administrative——————————
Total operating expenses(109)(149)(166)(190)(224)(256)(352)(440)(614)(772)
Operating income20283516(16)(40)(35)471111
Interest expense(11)(11)(15)(13)(9)(12)(28)(32)(34)(33)
Interest & investment income——————————
Other income (expense), net00(1)00(4)10(4)2
Pre-tax income916203(26)(56)(63)20(22)96
Income tax expense(5)(17)(5)(3)(3)(13)(15)(1)(4)(17)
Net income4(1)156(23)(43)(48)19(19)78
EPS — basic$0.34($0.09)$1.31$0.51($1.88)($3.40)($3.05)$0.86($1.04)$3.50
EPS — diluted$0.34($0.09)$1.30$0.50($1.88)($3.40)($3.05)$0.85($1.04)$3.32
Shares outstanding — basic (M)11121212121316181920
Shares outstanding — diluted (M)12121212121316181921

Showing the latest 10 of 17 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.